Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | ANPEP | P15144 | 5/20 | 0.46 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.46 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.39 |
| ▸ | LAP3 | P28838 | 2/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL196338 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL76796 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| SCHEMBL29783468 | 1.00 | SLC7A5 (0.56) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL353346 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL355415 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Methyl Alcohol SCHEMBL28477033 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL76795 | 0.98 | SLC7A5 (0.54) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Hydrochloric Acid SCHEMBL1532654 | 0.96 | SLC7A5 (0.52) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Alanine SCHEMBL7256054 | 0.92 | SLC7A5 (0.59) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 | |
| Leucine SCHEMBL10382490 | 0.92 | SLC7A5 (0.72) | SLC7A5ANPEPRNPEPDNPEPSLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 321 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118165047-A | A series of sophorolipid derivatives and glucose lipid derivatives, and preparation method and application thereof | 南京理工大学 | 2024-06-11 | — | — | CN | claimed |
| CN-115232130-B | APN and AKT double-target inhibitor and preparation method and application thereof | 山东大学 | 2024-01-12 | — | — | CN | claimed |
| CN-110240582-B | Flavone derivative with tumor cell inhibiting function and preparation method and application thereof | 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) | 2022-11-01 | — | — | CN | claimed |
| CN-115232130-A | APN and AKT double-target-point inhibitor and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | claimed |
| CN-114181116-A | D-amino acid derivative aminopeptidase N inhibitor and preparation method and application thereof | 山东中医药大学 | 2022-03-15 | — | — | CN | claimed |
| CN-112979485-A | Application of 3A type molecular sieve in synthesis of N- (4-acetylene benzene carbonyl) amino acid ester | 齐鲁工业大学 | 2021-06-18 | — | — | CN | claimed |
| CN-108578399-B | Application of amino acid ester compound in preparation of anti-CVB 3 virus medicine | 湖北工业大学 | 2020-01-07 | — | — | CN | claimed |
| US-12616732-B2 | Peptides for treatment of medical disorders | YICHANG HUMANWELL PHARMACEUTICALS CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| CN-119836295-A | Peptides for the treatment of medical conditions | 人福医药美国公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025041931-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF SARCOPENIA IN COMPANION ANIMALS | 마이오펫 주식회사 | 2025-02-27 | — | — | WO | disclosed |
| CN-119100942-A | Juglone-amino acid ester derivative, synthesis method thereof and application thereof in biological antibacterial agent | 江苏科技大学 | 2024-12-10 | — | — | CN | disclosed |
| EP-3398452-B1 | COMESTIBLE COMPOSITIONS COMPRISING HIGH POTENCY SAVORY FLAVORANTS | FIRMENICH INCORPORATED (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-0543858-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| US-5200412-A | Antiinflammatory agents and antiallergens | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-04-06 | — | — | US | disclosed |
| WO-1992003423-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| US-4616002-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1986-10-07 | — | — | US | disclosed |
| US-4487717-A | PHASE SEPARATION USING ORGANIC SOLVENT | TOYO SODA MANUFACTURING CO., LTD. (JP) | 1984-12-11 | — | — | US | disclosed |
| EP-0038046-B1 | PHARMACEUTICAL AMIDES, AND PREPARATION, FORMULATIONS AND USE THEREOF | THE WELLCOME FOUNDATION LIMITED (GB) | 1984-02-29 | — | — | EP | disclosed |
| EP-0038046-A2 | Pharmaceutical amides, and preparation, formulations and use thereof | THE WELLCOME FOUNDATION LIMITED (GB) | 1981-10-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12616732-B2 | Peptides for treatment of medical disorders | OPRK1, OPRD1, OPRL1 | SLC7A5 1658/4885ANPEP 1311/4885RNPEP 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.